# John Gustofson

> John Gustofson is a Series A investor at Chugai Venture Fund backing Biotechnology and Medical. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Chugai Venture Fund](https://shizune.co/investors/profile/chugai-venture-fund)
- Location: Boston, United States
- Total investments: 10
- Last investment: Feb 2026
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/john-gustofson-95022b1/
- Facebook: https://www.facebook.com/john.gustofson

John Gustofson is a Series A investor at Chugai Venture Fund in Boston focused on Biotechnology and Medical. John Gustofson is the Founder and President of Chugai Venture Fund. He previously worked at AbbVie as a Managing Director. John Gustofson attended Questrom School of Business, Boston University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 40% |
| Medical | 2 | 20% |
| Health Care | 2 | 20% |
| Therapeutics | 2 | 20% |
| Pharmaceutical | 2 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 40% |
| Seed | 1 | 10% |
| Funding Round | 1 | 10% |
| Debt Financing | 1 | 10% |
| Venture - Series Unknown | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ten63 Therapeutics | Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. |  | Venture - Series Unknown | Feb 19, 2026 |  |
| Leal Therapeutics | Leal Therapeutics develops novel therapeutics for patients. | $30M | Series A | Aug 27, 2025 |  |
| Stylus Medicine | Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders. The company is based in Cambridge, Massachusetts. | $85M | Series A | May 12, 2025 |  |
| Leal Therapeutics | Leal Therapeutics develops novel therapeutics for patients. |  | Debt Financing | Oct 30, 2024 |  |
| Leal Therapeutics | Leal Therapeutics develops novel therapeutics for patients. | $6M | Venture - Series Unknown | Oct 30, 2024 |  |
| Caraway Therapeutics | Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multipleneurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases. | $23M | Series A | Nov 26, 2018 |  |
| Caraway Therapeutics | Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multipleneurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases. | $23M | Series A | Nov 26, 2018 |  |
| Ribometrix | Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston. | $30M | Series A | Nov 13, 2018 |  |
| Ribometrix | Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston. | $7.5M | Seed | Oct 31, 2017 |  |
| Ribometrix | Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston. | $7.5M | Seed | Oct 31, 2017 |  |

10 of 10 investments shown.

## Co-investors
- [Dementia Discovery Fund](https://shizune.co/investors/profile/dementia-discovery) — VC Fund, 6 deals together
- [SV Health Investors](https://shizune.co/investors/profile/sv-life-sciences) — VC Fund, 5 deals together
- [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 4 deals together
- [AbbVie Biotech Ventures](https://shizune.co/investors/profile/abbvie-biotech-ventures) — VC Fund, 3 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 3 deals together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 3 deals together

## About Chugai Venture Fund

VC Fund · Boston, United States

Chugai Venture Fund is a pioneering investment firm that promotes innovation and creates revolutionary improvements in the life sciences industry.

2 contacts available at Chugai Venture Fund.

| Name | Title | Profile |
| --- | --- | --- |
| John Gustofson | Founder & President | https://shizune.co/investors/profile/john-gustofson |
| Mike Dial | Managing Director | https://shizune.co/investors/profile/mike-dial-742c |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does John Gustofson invest in?

John Gustofson invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did John Gustofson last invest?

The most recent investment recorded for John Gustofson closed in Feb 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co